← All trials
NCT06088784
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 19, 2023
- Primary completion
- Apr 24, 2024
- Completion date
- Apr 24, 2024
- First posted
- Oct 18, 2023
- Last posted
- Nov 18, 2023
- Enrollment
- 76
- Arms / groups
- 8 / —
- Source
- AACT · ctgov ingestion
Sponsors
- HanAll BioPharma Co., Ltd.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.